Sihe Zhang | Medicine | Distinguished Scientist Award

Distinguished Scientist Award

Sihe Zhang
Nankai University, China

Sihe Zhang
Affiliation Nankai University
Country China
Scopus ID 7409373738
Documents 55
Citations 1,269
h-index 16
Subject Area Medicine
Event Scientific World Research Awards
ORCID 0000-0002-8923-1993

The Distinguished Scientist Award recognizes the scholarly achievements of Sihe Zhang, Professor and Director at Nankai University School of Medicine. His research focuses on cancer biology, drug delivery systems, endocytosis, extracellular vesicles, antibody therapeutics, and translational medicine. Through sustained contributions to hepatocellular carcinoma and ovarian cancer research, he has developed innovative approaches that connect molecular mechanisms with therapeutic applications.[1]

Abstract

Sihe Zhang is a biomedical researcher whose work spans cancer biology, antibody engineering, cellular uptake mechanisms, extracellular vesicle biology, and targeted therapeutic delivery. His investigations have contributed to understanding macropinocytosis, endocytic recycling, tumor progression, and resistance mechanisms in hepatocellular and ovarian cancers. He has also participated in the development of innovative antibody-based therapies and nanomedicine strategies aimed at improving treatment specificity and efficacy. His publication portfolio demonstrates a sustained commitment to translational medical research and interdisciplinary collaboration, supporting advancements in cancer diagnosis, drug delivery, and precision medicine.[1][2]

Keywords

Cancer Biology; Drug Delivery; Endocytosis; Extracellular Vesicles; Antibody Therapeutics; Hepatocellular Carcinoma; Ovarian Cancer; Nanomedicine.

Introduction

Professor Zhang has held academic positions at Nankai University and previously at the Fourth Military Medical University. His career reflects long-term engagement with molecular medicine and cell biology, emphasizing mechanisms that influence cancer progression and treatment response.[1]

Research Profile

His research profile combines laboratory discovery with translational applications. Major themes include cellular trafficking, therapeutic antibodies, tumor microenvironment studies, and targeted delivery platforms designed to improve treatment outcomes in oncology.[1]

Research Contributions

Notable contributions include investigations into CD147-mediated signaling, extracellular vesicle uptake, macropinocytosis-driven drug resistance, and antibody-based cancer therapies. These studies have expanded understanding of tumor biology and therapeutic targeting strategies.[2][3]

Publications

His scholarly record includes 55 indexed publications. Representative works address hepatocellular carcinoma resistance mechanisms, extracellular vesicle biology, peptide delivery systems, anti-CD147 therapeutics, and nanobiotechnology-based treatment approaches.[2][4]

Research Impact

With 1,269 citations and an h-index of 16, his research has influenced studies in cancer therapeutics, molecular oncology, and biomedical engineering. The impact of his work is reflected through citations, collaborations, and peer-review activities across leading journals.[1]

Award Suitability

The breadth of Professor Zhang’s contributions, combined with sustained publication output and translational relevance, aligns with the objectives of the Scientific World Research Awards. His work demonstrates scientific rigor and practical relevance in medicine.[1]

Conclusion

Sihe Zhang has established a recognized research portfolio in cancer biology and therapeutic innovation. His scholarly achievements and ongoing contributions support recognition through the Distinguished Scientist Award.[1]

References

  1. ORCID. (2026). Sihe Zhang (0000-0002-8923-1993) Research Profile.https://orcid.org/0000-0002-8923-1993
  2. Qian, L., et al. (2025). The uptake of extracellular vesicles: Research progress in cancer drug resistance and beyond. Drug Resistance Updates.https://doi.org/10.1016/j.drup.2025.101209
  3. Qi, F.Z., et al. (2024). Hypoxia-activated ADCC-enhanced humanized anti-CD147 antibody. MedComm.https://doi.org/10.1002/mco2.512
  4. Sun, Z., et al. (2023). Cell-Penetrating Peptide-Based Delivery of Macromolecular Drugs. Biomedicines.https://doi.org/10.3390/biomedicines11071971
  5. Wang, B., et al. (2024). Hypoxia-activated selectivity-improved anti-PKM2 antibody combined with prodrug TH-302. International Journal of Biological Sciences.https://doi.org/10.7150/ijbs.92211

Asterios Deligiannis | Medicine | Best Innovation Award

Best Innovation Award

Asterios Deligiannis

Researcher Information
Affiliation Aristotle University of Thessaloniki
Country Greece
Scopus ID 7003501457
Documents 127
Citations 5,944
h-index 28
Subject Area Chemistry
Event Scientific World Research Awards
ORCID 0000-0001-7765-1897

Asterios Deligiannis is an academic affiliated with Aristotle University of Thessaloniki, Greece. His scholarly record demonstrates extensive research productivity, interdisciplinary collaboration, and sustained scientific contribution. According to available research metrics, he has produced 127 indexed publications, received 5,944 citations, and achieved an h-index of 28, reflecting broad academic visibility and influence across multiple research domains.[1][2]

Abstract

This article presents an overview of the academic achievements of Asterios Deligiannis. His research portfolio encompasses a substantial body of scholarly work, international collaborations, and contributions to scientific knowledge. Available publication metrics indicate 127 indexed documents, 5,944 citations, and an h-index of 28, reflecting sustained research productivity and scholarly influence.[1] His academic activities include participation in international research initiatives, professional organizations, and peer-reviewed publications. These accomplishments demonstrate innovation, research leadership, and measurable scientific impact, supporting consideration for recognition through the Best Innovation Award within an international academic framework.[2]

Keywords

Innovation, Chemistry, Scientific Research, Academic Impact, Research Excellence, Scholarly Contributions.

Introduction

Research innovation is commonly assessed through scientific productivity, influence, and contributions to knowledge development. Academic recognition programs frequently consider publication records, citation performance, and interdisciplinary engagement when evaluating researchers for distinguished awards.[1]

Research Profile

Deligiannis is affiliated with Aristotle University of Thessaloniki and maintains an active ORCID record. His professional activities include academic leadership, international memberships, and participation in collaborative research programs.[2]

Research Contributions

His scholarly contributions span cardiovascular health, exercise-related investigations, rehabilitation studies, and interdisciplinary scientific research. Numerous peer-reviewed publications demonstrate long-term engagement in advancing evidence-based knowledge and innovation.[3]

Publications

The researcher has authored 127 indexed publications and contributed to a broad collection of scientific articles published in international journals. His publication record reflects sustained scholarly activity and extensive collaboration across research communities.[1]

Research Impact

Research influence is demonstrated through 5,944 citations and an h-index of 28. These indicators suggest significant academic visibility and continuing relevance of his publications within scientific literature and research networks.[1]

Award Suitability

The combination of research productivity, scholarly impact, international engagement, and documented scientific contributions supports consideration for the Best Innovation Award. His profile reflects characteristics commonly associated with academic distinction and innovation-oriented recognition.[1]

Conclusion

Asterios Deligiannis has established a substantial academic record characterized by impactful publications, collaborative research activities, and measurable scholarly influence. These achievements provide a strong foundation for recognition within international research award programs.

References

  1. Elsevier. (n.d.). Scopus Author Details: Asterios Deligiannis, Author ID 7003501457. Scopus.

    https://www.scopus.com/authid/detail.uri?authorId=7003501457

  2. ORCID. (2026). Asterios Deligiannis ORCID Record.

    https://orcid.org/0000-0001-7765-1897

  3. Deligiannis, A., et al. (2025). Investigating the Role of Exercise in Improving Bone Health Among Elderly Women with Osteopenia.

    https://doi.org/10.3390/jfmk10040451

  4. Deligiannis, A., et al. (2025). Advanced Stress Echocardiography with Cardiopulmonary Exercise Testing After Myocardial Infarction.

    https://doi.org/10.3390/jfmk10040393

  5. Scientific World Research Awards. (n.d.). Official Award Information Portal.

    https://scientificworld.net/

Yoshiya Tanaka | Medicine | Innovative Research Award

Innovative Research Award

Yoshiya Tanaka

Yoshiya Tanaka
Affiliation Hospital of University of Occupational and Environmental Health
Country Japan
Scopus ID 56328279400
Documents 1,326
Citations 50,831
h-index 99
Subject Area Medicine
Event Scientific World Research Awards

Yoshiya Tanaka, Hospital of University of Occupational and Environmental Health, Japan, is recognized for substantial contributions to rheumatology, immunology, and autoimmune disease research. His scholarly output, clinical investigations, and leadership in international collaborations have supported advancements in evidence-based medical practice and therapeutic development.[1]

Abstract

The Innovative Research Award recognizes researchers whose work demonstrates sustained scientific excellence and measurable impact. Yoshiya Tanaka has contributed extensively to rheumatology and clinical immunology through studies on autoimmune diseases, inflammatory mechanisms, biologic therapies, and targeted treatments. His research has informed clinical guidelines, improved disease classification systems, and supported the development of therapeutic strategies for conditions such as systemic lupus erythematosus, rheumatoid arthritis, and IgG4-related disease. With a substantial publication record and broad international collaboration, his work has influenced both academic research and patient care, reflecting the objectives of the Scientific World Research Awards.[1][2]

Keywords

Rheumatology, Clinical Immunology, Autoimmune Diseases, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Biologic Therapy, Translational Medicine.

Introduction

Modern rheumatology depends on interdisciplinary research linking immunology, molecular biology, and clinical practice. Yoshiya Tanaka has participated in investigations that enhanced understanding of inflammatory pathways and treatment approaches for immune-mediated diseases.[3]

Research Profile

As Professor and Chairman in rheumatology and clinical immunology, Tanaka has developed a research portfolio focused on disease mechanisms, therapeutic innovation, and clinical trial leadership. His scholarly record reflects long-term engagement with translational medicine and global collaboration.[1]

Research Contributions

Key contributions include studies supporting lupus classification criteria, IgG4-related disease frameworks, Janus kinase inhibitor development, and biologic treatment evaluation. These efforts have contributed to improved disease assessment and therapeutic decision-making.[2][4]

Publications

  • 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus.
  • Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
  • Janus Kinase-Targeting Therapies in Rheumatology.

Research Impact

The researcher’s publications have received extensive citations, demonstrating influence across clinical medicine and immunology. Findings from collaborative studies have informed guidelines, therapeutic development, and evidence-based healthcare practices internationally.[1][5]

Award Suitability

The breadth of scientific output, citation performance, clinical relevance, and leadership in collaborative research aligns with the objectives of the Innovative Research Award. His contributions demonstrate sustained scholarly influence and practical significance in medicine.

Conclusion

Yoshiya Tanaka’s career reflects a consistent commitment to advancing knowledge in rheumatology and autoimmune disease research. His achievements support recognition within international scientific award programs and academic communities.

References

  1. Elsevier. (n.d.). Scopus author details: Yoshiya Tanaka, Author ID 56328279400. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=56328279400
  2. Aringer, M., et al. (2019). 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus.
    DOI: https://doi.org/10.1002/art.40930
  3. Tanaka, Y., Adams, D.H., & Shaw, S. (1993). T-cell Adhesion Induced by Proteoglycan-Immobilized Cytokine MIP-1β.
    DOI: https://doi.org/10.1038/361079a0
  4. Tanaka, Y., Luo, Y., O’Shea, J.J., & Nakayamada, S. (2022). Janus Kinase-Targeting Therapies in Rheumatology.
    DOI: https://doi.org/10.1038/s41584-021-00726-8
  5. Google Scholar. (2026). Yoshiya Tanaka Citation Profile.
    https://scholar.google.com/citations?user=t_hAg7QAAAAJ&hl=en

Sedanur Güngör | Public Health | Best Researcher Award

Best Researcher Award

Sedanur Güngör

Sedanur Güngör
Affiliation Gazi University
Country Turkey
Scopus ID 59374926100
Documents 4
Citations 5
h-index 1
Subject Area Public Health
Event Scientific World Research Awards
ORCID 0000-0002-3943-5365

Sedanur Güngör is a researcher affiliated with Gazi University whose academic work contributes to the fields of physiotherapy, rehabilitation sciences, and public health. Her scholarly profile includes studies related to hand rehabilitation, telerehabilitation methods, musculoskeletal disorders, and clinical assessment tools.[1] Through collaborative clinical investigations, her research reflects contemporary approaches in rehabilitation practice and patient-centered physiotherapy applications.[2]

Abstract

Sedanur Güngör has developed an emerging academic profile in public health and physiotherapy research through collaborative investigations focusing on rehabilitation sciences and clinical patient outcomes. Her published studies address telerehabilitation, grip strength evaluation, osteoarthritis, tendon repair, and virtual assessment methods in physiotherapy practice.[2] These contributions demonstrate engagement with evidence-based rehabilitation techniques and modern therapeutic technologies. Her scholarly activities also include psychometric and clinical investigations intended to improve patient care and rehabilitation efficiency.[3] The interdisciplinary nature of her work reflects the evolving integration of digital healthcare systems into rehabilitation sciences.

Keywords

Public Health, Physiotherapy, Rehabilitation Sciences, Telerehabilitation, Hand Therapy, Clinical Research

Introduction

Current rehabilitation sciences increasingly incorporate digital assessment methods and patient-centered therapy models. Sedanur Güngör’s research activity aligns with these developments through investigations involving hand rehabilitation and therapeutic evaluation systems.[2]

Research Profile

Her Scopus-indexed publications and ORCID profile document collaborative studies in physiotherapy and rehabilitation medicine. Research topics include tendon repair rehabilitation, osteoarthritis interventions, and psychometric clinical measurements.[1]

Research Contributions

Her published investigations evaluate rehabilitation effectiveness, virtual goniometric measurements, and radial nerve mobilization outcomes in clinical populations.[3] These studies contribute to evidence-based physiotherapy literature.

Publications

Research Impact

The researcher’s contributions support ongoing advancements in rehabilitation assessment and therapeutic monitoring. Her work demonstrates practical relevance for physiotherapy professionals and clinical rehabilitation researchers.[4]

Award Suitability

Sedanur Güngör’s emerging publication profile, interdisciplinary rehabilitation studies, and contributions to clinical physiotherapy research support her recognition for the Best Researcher Award under the Scientific World Research Awards program.[5]

Conclusion

The academic activities of Sedanur Güngör reflect a developing contribution to rehabilitation sciences and public health research through clinically focused physiotherapy investigations and collaborative scholarly work.

References

  1. ORCID. (2026). Sedanur Güngör researcher profile and scholarly works.
    https://orcid.org/0000-0002-3943-5365?lang=en
  2. Elsevier. (n.d.). Scopus author details: Sedanur Güngör, Author ID 59374926100. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=59374926100
  3. Güngör, S., et al. (2026). Virtual goniometric measurement in patients with hand and forearm injuries.
    DOI: https://doi.org/10.1080/09638288.2026.2663904
  4. Güngör, S., et al. (2026). Investigation of the effect of radial nerve mobilization on pain, function, and grip strength.
    DOI: https://doi.org/10.1016/j.physio.2026.102328
  5. Scientific World. (2026). Scientific World Research Awards official website.
    https://scientificworld.net/

Lina Posada Calderon | Medicine | Research Excellence Award

Dr. Lina Posada Calderon | Medicine | Research Excellence Award

Resident | New York Presbyterian | United States

Dr. Lina Posada Calderon is an accomplished biomedical researcher at Weill Cornell Medicine, New York, specializing in translational and molecular cancer research. Her work focuses on the clinical and molecular characterization of cancers, precision oncology, biomarker discovery, and genetic drivers of tumor progression, with particular emphasis on KRAS-mutated malignancies. She has strong expertise in molecular biology, cancer genomics, clinical data analysis, interdisciplinary research, and high-impact scientific publishing. Her research bridges laboratory discoveries with patient-centered clinical outcomes. Dr. Posada Calderon has published 12 Scopus-indexed documents, receiving 61 citations, and holds an h-index of 5, reflecting her growing scholarly impact and emerging leadership in precision cancer research.

 

Citation Metrics (Scopus)

61
45
30
15
0

Citations

61

Documents

12

h-index

5

Citations

Documents

h-index

View Scopus Profile
View Google Scholar

Featured Publications

 

Philipp Kanske | Medicine | Research Excellence Award

Prof. Dr. Philipp Kanske | Medicine | Research Excellence Award

Professor | TUD Dresden University of Technology | Germany

Prof. Dr. Philipp Kanske is an internationally recognized expert in cognitive and affective neuroscience whose work bridges psychology, social cognition, neuroimaging, and mental health research. His research centers on empathy, compassion, emotion regulation, personality functioning, and the neurobiological mechanisms that shape human social behavior across the lifespan. He investigates how individuals perceive and respond to others’ emotions, how empathic stress is transmitted within families, and how interventions such as meditation and compassion training can induce functional neural plasticity and improve emotional well-being, particularly in older adults. His interests extend to personality organization in both clinical and non-clinical populations, disease progression in bipolar disorder, white-matter microstructure, attachment dynamics in couples, value integration for self and others, and ritual-based methods for strengthening human–nature connectedness in the context of sustainability transformations. Prof. Kanske is skilled in a wide range of methodologies including experimental psychology, behavioral analysis, longitudinal study design, cognitive testing, psychoneuroendocrinology, structural and functional MRI, and advanced statistical modeling. His contributions to research transparency and reproducibility are reflected in his leadership in developing the PECANS methodological framework for cognitive and neuropsychological studies. Throughout his career, he has received multiple awards and honors (as listed in Scopus’s “Awarded Grants” section), recognizing his innovative contributions to social neuroscience, aging research, and clinical psychology. According to Scopus Preview, he has 7,136 citations, 163 documents, and an impressive h-index of 43, underscoring his global scientific influence and sustained scholarly productivity. Overall, Prof. Dr. Philipp Kanske’s work provides significant insights into how emotional, neural, and relational processes shape human behavior, offering important implications for mental health, interpersonal functioning, and societal well-being, and solidifying his role as a leading figure in modern neuroscience and psychology.

ProfilesScopus | ORCID | Google Scholar

Featured Publications

  1. Kanske, P., Heissler, J., Schönfelder, S., Bongers, A., & Wessa, M. (2011). How to regulate emotion? Neural networks for reappraisal and distraction. Cerebral Cortex, 21(6), 1379–138.
    Citations: 698

  2. Schurz, M., Radua, J., Tholen, M. G., Maliske, L., Margulies, D. S., Mars, R. B., … Kanske, P. (2021). Toward a hierarchical model of social cognition: A neuroimaging meta-analysis and integrative review of empathy and theory of mind. Psychological Bulletin, 147(3), 293–. Citations: 648

  3. Kanske, P., & Kotz, S. A. (2007). Concreteness in emotional words: ERP evidence from a hemifield study. Brain Research, 1148, 138–148. Citations: 630

  4. Preckel, K., Kanske, P., & Singer, T. (2018). On the interaction of social affect and cognition: Empathy, compassion and theory of mind. Current Opinion in Behavioral Sciences, 19, 1–6.
    Citations: 554

  5. Moshontz, H., Campbell, L., Ebersole, C. R., IJzerman, H., Urry, H. L., Forscher, P. S., … Kanske, P. (2018). The Psychological Science Accelerator: Advancing psychology through a distributed collaborative network. Advances in Methods and Practices in Psychological Science, 1(4), 501–515. Citations: 499

Prof. Dr. Philipp Kanske’s work advances global scientific understanding of empathy, compassion, and emotion regulation by uncovering the neural and psychological mechanisms that drive healthy social functioning. His research enables evidence-based mental-health interventions, strengthens human well-being across communities, and supports interdisciplinary innovation in neuroscience, clinical psychology, aging research, and societal resilience.

 

Hengrui Liu | Medicine | Best Researcher Award

Prof. Dr. Hengrui Liu | Medicine | Best Researcher Award

Researcher | University of Cambridge | United Kingdom

Dr. Hengrui Liu is a distinguished researcher at the University of Cambridge, United Kingdom, whose interdisciplinary work spans molecular biology, oncology, pharmacogenomics, and bioinformatics. With a remarkable Scopus h-index of 31, over 2,300 citations, and 55 publications, Dr. Liu has made substantial contributions to understanding cancer biology and translational medicine. His research integrates computational modeling, systems biology, and experimental oncology, focusing on identifying molecular mechanisms underlying drug resistance, tumor progression, and therapeutic targeting.One of Dr. Liu’s notable contributions includes the use of CRISPR screening and cell line IC50 data to uncover genes responsible for trametinib resistance, highlighting potential pathways for targeted cancer therapy. He also explores the role of transcription factors in protein autoubiquitination across multiple cancer types through pan-cancer in-silico profiling, advancing precision oncology approaches. His expertise extends to traditional medicine and integrative therapies, as seen in his recent studies on the role of traditional Chinese medicine (TCM) in improving liver transplantation outcomes, bridging conventional and modern biomedical practices.Dr. Liu’s recent review on the multidimensional role of laminin γ2 (LAMC2) in cancer progression provides a comprehensive understanding of how extracellular matrix components influence tumor behavior and metastasis. His interdisciplinary research brings together molecular mechanisms, clinical relevance, and computational insight, reflecting a holistic approach to biomedical innovation. Moreover, his collaborative network of over 100 co-authors underscores his global impact and leadership in international scientific research.Through his pioneering studies, Dr. Hengrui Liu contributes to the development of novel therapeutic strategies, drug resistance biomarkers, and predictive computational frameworks that enhance the diagnosis, treatment, and prognosis of complex diseases such as cancer. His work exemplifies the synergy between data-driven research and molecular experimentation, reinforcing his reputation as a forward-thinking scientist shaping the future of personalized medicine and biomedical innovation.

Profiles: Scopus | ORCID | Google Scholar

Featured Publications

Liu, H., et al. (2025). CRISPR screening and cell line IC50 data reveal novel key genes for trametinib resistance. Open-access Letter. 26 citations.

Liu, H., et al. (2025). In vitro antibacterial activity of neochebulinic acid from aqueous extract of Terminalia chebula Retz against Helicobacter pylori. BMC Complementary Medicine and Therapies. 1 citation.

Liu, H., et al. (2025). An in-silico pan-cancer bulk and single-cell profiling of transcription factors in protein autoubiquitination. Discover Oncology. 2 citations.

Liu, H., et al. (2025). The multidimensional role of laminin γ2 (LAMC2) on cancer progression. Review Article. 0 citations.

Liu, H., et al. (2025). Role of traditional Chinese medicine in supporting liver transplantation outcomes. World Journal of Transplantation. 4 citations.

Manouchehr Ashrafpour | Medicine | Best Scholar Award

Dr. Manouchehr Ashrafpour | Medicine | Best Scholar Award

Faculty Member | Babol University of Medical Sciences | Iran

Dr. Manouchehr Ashrafpour is a prominent neuroscientist and biomedical researcher at Babol University of Medical Sciences, renowned for his extensive contributions to neuropharmacology, molecular neuroscience, and neurodegenerative disease research. He earned his advanced degrees in medical sciences and neuroscience, building a strong academic foundation that bridges cellular biology and clinical neurotherapeutics. Throughout his professional career, Dr. Ashrafpour has demonstrated exceptional expertise in experimental neurobiology, drug delivery systems, and the molecular mechanisms underlying brain disorders such as Alzheimer’s disease, Parkinson’s disease, epilepsy, and multiple sclerosis. His research primarily focuses on the neuroprotective effects of natural bioactive compounds and nanotechnology-based formulations, including curcumin-, piperine-, arbutin-, and quercetin-loaded nanoparticles, which have shown promising results in reducing oxidative stress, glial activation, and neuronal degeneration. He possesses advanced research skills in animal modeling, histopathological assessment, biochemical analysis, neurobehavioral testing, and nanomedicine formulation, complemented by a strong command of cellular electrophysiology and molecular signaling studies. His professional experience encompasses collaborations with leading neuroscientists on projects exploring the role of vitamins, antioxidants, and receptor modulation (notably adenosine A2A receptor blockade) in promoting neural repair and functional recovery. Dr. Ashrafpour’s scholarly achievements are reflected in his strong Scopus record, which includes over 700 citations, numerous peer-reviewed documents, and an h-index of 17, underscoring his global academic influence. He has received recognition and academic honors for his innovative work in neurotherapeutic discovery and translational neuroscience, highlighting his commitment to improving treatment strategies for neurodegenerative diseases. In conclusion, Dr. Manouchehr Ashrafpour stands as a distinguished figure in contemporary neuroscience, whose multidisciplinary approach—spanning nanotechnology, pharmacology, and neurobiology—continues to shape the future of neuroprotective medicine and inspire emerging researchers in biomedical sciences worldwide.

Profiles: ORCID | Google Scholar 

Featured Publications

  1. Naeimi, R., Safarpour, F., Hashemian, M., Tashakorian, H., Ahmadian, S. R., & Ashrafpour, M. (2018). Curcumin-loaded nanoparticles ameliorate glial activation and improve myelin repair in lyolecithin-induced focal demyelination model of rat corpus callosum. Neuroscience Letters, 674, 1–10. Cited by 71.

  2. Mansoor, S. R., Hashemian, M., Khalili-Fomeshi, M., Ashrafpour, M., & Moghadamnia, A. A. (2018). Upregulation of klotho and erythropoietin contributes to the neuroprotection induced by curcumin-loaded nanoparticles in an experimental model of chronic epilepsy. Brain Research Bulletin, 142, 281–288. Cited by 52.

  3. Khalili-Fomeshi, M., Azizi, M. G., Esmaeili, M. R., Gol, M., Kazemi, S., & Ashrafpour, M. (2018). Piperine restores streptozotocin-induced cognitive impairments: Insights into oxidative balance in cerebrospinal fluid and hippocampus. Behavioural Brain Research, 337, 131–138. Cited by 49.

  4. Dastan, Z., Pouramir, M., Ghasemi-Kasman, M., Ghasemzadeh, Z., Dadgar, M., & Ashrafpour, M. (2019). Arbutin reduces cognitive deficit and oxidative stress in an animal model of Alzheimer’s disease. International Journal of Neuroscience, 129(11), 1145–1153. Cited by 45.

  5. Dadgar, M., Pouramir, M., Dastan, Z., Ghasemi-Kasman, M., & Ashrafpour, M. (2018). Arbutin attenuates behavioral impairment and oxidative stress in an animal model of Parkinson’s disease. Avicenna Journal of Phytomedicine, 8(6), 533–540. Cited by 43.

 

 

Hugh Sampson | Medicine | Best Researcher Award

Dr. Hugh Sampson | Medicine | Best Researcher Award

Professor of Pediatrics | Icahn School of Medicine at Mount Sinai | United States

Dr. Hugh A. Sampson, MD, is a distinguished physician-scientist and pediatric immunologist best known for his pioneering contributions in food allergy and immunopathogenesis, and is currently the Kurt Hirschhorn Professor of Pediatrics and Director Emeritus of the Jaffe Food Allergy Institute at the Icahn School of Medicine at Mount Sinai. He earned a B.A. in Biology from Hamilton College in 1971, then obtained his M.D. from SUNY Buffalo in 1975, followed by a pediatric residency at Northwestern University / Children’s Memorial Hospital and an allergy/immunology fellowship at Duke University (1978–1980). Over his career, he has held leadership roles including chairing the Section on Allergy & Immunology of the American Academy of Pediatrics, serving as past President of AAAAI, holding editorial board positions in leading allergy/immunology journals, and directing national food allergy research consortia. His research interests encompass the pathogenesis of food-induced anaphylaxis, the molecular and immunologic characterization of allergenic food proteins and epitopes, genetics and immune regulation in food allergy, development of precision diagnostics (e.g. epitope-specific IgE/IgG4 profiles), and immunotherapy strategies (oral, epicutaneous, sublingual, and biologics such as anti-IgE) as well as novel therapeutic approaches. His research skills include translational and clinical trial design, immunologic assays (e.g. epitope mapping, serologic biomarkers), mechanistic in vitro and in vivo models, bioinformatics integration, large cohort epidemiologic and registry studies, and mentoring interdisciplinary teams. Among his many awards and honors are election to the National Academy of Medicine (Institute of Medicine) in 2003, the Brett Ratner Award from the American Academy of Pediatrics, the Distinguished Scientist Award of AAAAI, memberships in honorary societies (Alpha Omega Alpha, Sigma Xi), and repeated recognitions from Research.com as a top immunology scientist. According to his institutional profile, his h-index (based on Scopus/Pure) is listed at ~85,982 (which appears anomalous and may reflect internal counting metrics), while bibliometric sources more conservatively report an h-index of ~147 with over 800+ publications; traditional citation counts exceed 100,000 across his work. In conclusion, Dr. Sampson’s career exemplifies a remarkable integration of basic immunology and clinical translation: his leadership, mentorship, and sustained high-impact scholarship have shaped the modern field of food allergy research, spawning diagnostic and therapeutic innovations and training generations of investigators in allergy and immunology.

Profiles: Scopus | ORCID 

Featured Publications

  1. Rose, N. R., Milisauskas, V., & Sampson, H. A. (1975). Species-specific tissue antigens. III. Immunological relationships of enzymic antigens in various species. Clinical and Experimental Immunology, 20, 359–370.

  2. Sampson, H. A., & Buckley, R. H. (1981). Human IgE synthesis in vitro: A reassessment. Journal of Immunology, 127, 829–834.

  3. Rich, K. C., Sampson, H. A., Edwards, N. L., & Fox, I. H. (1981). Familial hypogammaglobulinemia with variable serum immunoglobulins: Concordance with lymphocyte ecto-5′-nucleotidase deficiency. American Journal of Diseases of Children, 135, 795–798.

  4. Sampson, H. A., Walchner, A., & Baker, P. (1981). Recurrent pyogenic infections in individuals with absence of the second component of complement. Journal of Clinical Immunology, 2, 39–45.

  5. LoGalbo, P. R., Sampson, H. A., & Buckley, R. H. (1982). Symptomatic giardiasis in three patients with X-linked agammaglobulinemia. Journal of Pediatrics, 101, 78–80.

 

 

Yigit Akin | Medicine | Best Researcher Award

Prof. Dr. Yigit Akin | Medicine | Best Researcher Award

Yigit Akin | Izmir Kâtip Celebi University School of Medicine | Turkey

Professor Yigit Akin is a distinguished urologist and academic leader specializing in uro-oncology, robotic surgery, and minimally invasive laparoscopy. He earned his M.D. from Ege University Faculty of Medicine in 2004 and completed advanced training in robotics, laparoscopy, and uro-oncology at Klinikum Heilbronn, Germany, between 2013 and 2014. Currently, he serves as Head of Urology at Izmir Katip Celebi University, Turkey, leading one of the country’s premier uro-oncology centers. With over 210 peer-reviewed publications, 14 book chapters, and editorial board memberships in international journals, his contributions are well recognized in PubMed and IEEE-indexed forums. He has directed multiple multidisciplinary and international research projects, notably pioneering the extraperitoneal laparoscopic radical prostatectomy using 3 trocars (#3trocarsELRP), with more than 1300 successful procedures. A global mentor in laparoscopic surgery, Prof. Akin has conducted live surgical workshops and training in over 10 countries, while also supervising international clinical fellows. His leadership extends to community-based medical training, editorial contributions, and professional memberships in leading medical and surgical associations. Prof. Akin is strongly positioned to lead next-generation cancer genetics and surgical innovation research. His expertise in developing novel laparoscopic techniques, combined with mentorship of global fellows, demonstrates the potential to advance robotic uro-oncology surgery, elevate Q1 journal contributions, and strengthen international collaborations that will shape the future of minimally invasive urology worldwide.

Profile: ORCID 

Featured Publications

orulmaz, E. M., Dönmez, K., Görgel, S. N., & Akin, Y. (2025). Penil fraktür nedeniyle opere edilen hastaların klinik sonuçları ve komplikasyonlarla ilişkili faktörler: 10 yıllık sonuçlarımız. Androloji Bülteni.

Tekinaslan, H., Görgel, S. N., & Akin, Y. (2025). Malekot kateter kırığına bağlı retroperitoneal yabancı cisim: Nadir bir olgu sunumu. Endouroloji Bülteni.

Dama, M., Yorulmaz, E. M., Özcan, S., Köse, O., Görgel, S. N., & Akin, Y. (2025). AISI, SIRI, and MLR in predicting surgical outcomes after radical cystectomy: Revisiting inflammatory risk markers. Medicina, 61(10), 1756.

Dama, M., Yorulmaz, E. M., Özcan, S., Köse, O., Görgel, S. N., & Akin, Y. (2025). Optimising imaging strategies in suspected urolithiasis: Effects on diagnostic and therapeutic timelines. Harran Üniversitesi Tıp Fakültesi Dergisi.

Özcan, S., Dama, M., Yorulmaz, E. M., Köse, O., Görgel, S. N., & Akin, Y. (2025). Holmium laser enucleation of the prostate and postoperative dysuria: A 20-year bibliometric perspective. Trends in Surgical Sciences.